PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants

PK MED, a French biotechnology company founded by Truffle Capital (founder of Abivax and Carvolix), developing therapeutic micro-implants to address major medical needs, today announces a significant strengthening of its governance. The company is strengthening the structure of its Board of Directors and Scientific Advisory Board to support the upcoming Phase 2 entry of its most advanced drug candidate, ARTHRELIS (treatment of gout flares), and to accelerate the preclinical development of ENGRAFTIS (treatment of poor graft function following bone marrow transplantation).

The Board of Directors of PK MED welcomes four key new members:

The Board of Directors is composed of: François Romaneix (Chairman of the Board), Isabelle Buckle, PhD, Prof. Daniel Hayoz, MD, Prof. Karine Lacombe, MD, Prof. Philippe Leboulch, MD, Dr. Philippe Pouletty, MD, Co-founder and CEO of Truffle Capital, founder of Abivax, Carvolix and PK MED, and Tom Tice, PhD.

PK MED’s Scientific Advisory Board welcomes two major medical figures:

The Scientific Advisory Board is composed of: Prof. Alain Fischer, MD, PhD (Chairman), Prof. Marie-Christophe Boissier, MD, PhD, Prof. Daniel Hayoz, MD, Prof. Philippe Leboulch, MD, Prof. Geraldine McCarthy, MD, Prof. Tuhina Neogi, MD, PhD, and Prof. Tristan Pascart, MD, PhD.

These appointments come during a period of acceleration for PK MED, backed by robust intellectual property and a differentiating local drug delivery approach for its two flagship projects:

François Romaneix, Chairman of the Board of Directors of PK MED, states: “ I am honored to join the Board of Directors of PK MED as Chairman, especially at a time when, in addition to the members already serving on the Board and the Scientific Advisory Board, we are welcoming such eminent figures from the healthcare, biotechnology, and medical research sectors into our governance bodies. Their complementary expertise in clinical and industrial development, drug delivery, and gene therapy are major assets that will support ARTHRELIS’s upcoming entry into a Phase 2 trial and accelerate the development of ENGRAFTIS. ”

***

About PK MED

PK MED is a French biotechnology company founded in 2019 by Truffle Capital, Business Builder and European leader in BioMedTech (founder of Abivax and Carvolix). PK MED develops injectable micro-implants for local drug delivery and cell homing.

Through its proprietary expertise and technical know-how, PK MED transforms established active ingredients into patented local therapies designed to maximize efficacy and safety by concentrating drug release directly at the targeted tissue while minimizing systemic exposure. PK MED has built a preclinical pipeline addressing major unmet medical needs, starting with gout flares (ARTHRELIS) and bone marrow transplantation (ENGRAFTIS).

View source version on businesswire.com: https://www.businesswire.com/news/home/20260729558997/en/

Contact

Media Contact – Primatice

Armand Rigaudy – armandrigaudy@primatice.com / +33 (0)7 88 96 41 84

© 2026 Business Wire, Inc.